Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05649059 · ClinicalTrials.gov registry record · Phase 4
Investigating the Effects of Cannabidiol on Social Anxiety Disorder
A Phase 4 study of Phobia, Social, sponsored by Massachusetts Institute of Technology.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05649059 is a Phase 4 study of Phobia, Social that is actively recruiting participants, run by Massachusetts Institute of Technology. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05649059, a Phase 4 study of Phobia, Social, is actively recruiting participants, sponsored by Massachusetts Institute of Technology.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test whether a single-dose of Epidiolex (cannabidiol) is associated with reduced psychological, physiological, and neuroimaging measures of anxiety in people diagnosed with social anxiety disorder (SAD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cannabidiol
Study Locations (1)
Massachusetts
- Massachusetts Institute of Technology - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-07-10 |
| Est. Completion | 2026-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05649059
The ClinicalTrials.gov registry entry for NCT05649059 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts Institute of Technology, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Phobia, Social appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05649059 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05649059 about?
NCT05649059 is a clinical study titled "Investigating the Effects of Cannabidiol on Social Anxiety Disorder". The purpose of this study is to test whether a single-dose of Epidiolex (cannabidiol) is associated with reduced psychological, physiological, and neuroimaging measures of anxiety in people diagnosed with social anxiety disorder (SAD).
What is the current status of trial NCT05649059?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2025-07-10. Estimated completion is 2026-09.
What conditions does trial NCT05649059 study?
This clinical trial studies the following conditions: Phobia, Social.
What interventions are being tested in trial NCT05649059?
The interventions under investigation include: Placebo (DRUG), Cannabidiol (DRUG).
Who is sponsoring clinical trial NCT05649059?
This trial is sponsored by Massachusetts Institute of Technology, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05649059 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.